PT3222280T - Aumento da biodisponibilidade farmacológica numa terapêutica com naltrexona - Google Patents

Aumento da biodisponibilidade farmacológica numa terapêutica com naltrexona

Info

Publication number: PT3222280T
Authority: PT; Portugal
Prior art keywords: drug bioavailability; increasing drug; naltrexone therapy; naltrexone; therapy
Prior art date: 2010-12-03

Application number

PT171569858T

Other languages

English (en)

Original Assignee

Nalpropion Pharmaceuticals Llc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-12-03

Filing date

2011-12-02

Publication date

2021-04-22

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46172304&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT3222280(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2011-12-02 Application filed by Nalpropion Pharmaceuticals Llc filed Critical Nalpropion Pharmaceuticals Llc

2021-04-22 Publication of PT3222280T publication Critical patent/PT3222280T/pt

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M21/00—Other devices or methods to cause a change in the state of consciousness; Devices for producing or ending sleep by mechanical, optical, or acoustical means, e.g. for hypnosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Emergency Medicine (AREA)
Engineering & Computer Science (AREA)
Hematology (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Diabetes (AREA)
Obesity (AREA)
Child & Adolescent Psychology (AREA)
Heart & Thoracic Surgery (AREA)
Acoustics & Sound (AREA)
Biomedical Technology (AREA)
Anesthesiology (AREA)
Physics & Mathematics (AREA)
Psychology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Coloring Foods And Improving Nutritive Qualities (AREA)
Medicinal Preparation (AREA)

PT171569858T 2010-12-03 2011-12-02 Aumento da biodisponibilidade farmacológica numa terapêutica com naltrexona PT3222280T (pt)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US41939510P	2010-12-03	2010-12-03

Publications (1)

Publication Number	Publication Date
PT3222280T true PT3222280T (pt)	2021-04-22

Family

ID=46172304

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
PT118451863T PT2646031T (pt)	2010-12-03	2011-12-02	Aumento da biodisponibilidade farmacológica numa terapêutica com naltrexona
PT171569858T PT3222280T (pt)	2010-12-03	2011-12-02	Aumento da biodisponibilidade farmacológica numa terapêutica com naltrexona
PT211523147T PT3884947T (pt)	2010-12-03	2011-12-02	Aumento da biodisponibilidade farmacológica numa terapêutica com naltrexona

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
PT118451863T PT2646031T (pt)	2010-12-03	2011-12-02	Aumento da biodisponibilidade farmacológica numa terapêutica com naltrexona

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
PT211523147T PT3884947T (pt)	2010-12-03	2011-12-02	Aumento da biodisponibilidade farmacológica numa terapêutica com naltrexona

Country Status (27)

Country	Link
US (1)	US20130245056A1 (pt)
EP (4)	EP4349369B1 (pt)
JP (5)	JP6008866B2 (pt)
KR (5)	KR102258043B1 (pt)
CN (1)	CN103313711A (pt)
AR (2)	AR093182A1 (pt)
AU (2)	AU2011336304B2 (pt)
BR (1)	BR112013013390A2 (pt)
CA (2)	CA3239386A1 (pt)
CL (1)	CL2013001564A1 (pt)
CY (2)	CY1118968T1 (pt)
DK (3)	DK3222280T3 (pt)
ES (2)	ES2866879T3 (pt)
FI (2)	FI3884947T3 (pt)
HR (3)	HRP20170734T1 (pt)
HU (3)	HUE053831T2 (pt)
IL (3)	IL226504B (pt)
LT (3)	LT3884947T (pt)
MX (2)	MX384662B (pt)
PL (3)	PL3222280T3 (pt)
PT (3)	PT2646031T (pt)
RS (3)	RS62149B1 (pt)
RU (1)	RU2640561C2 (pt)
SI (3)	SI3884947T1 (pt)
SM (3)	SMT201700232T1 (pt)
TW (1)	TWI618536B (pt)
WO (1)	WO2012075459A1 (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
MXPA05011557A (es)	2003-04-29	2006-03-09	Orexigen Therapeutics Inc	Composiciones para afectar perdida de peso.
EP2292220A3 (en)	2005-11-22	2012-01-04	Orexigen Therapeutics, Inc.	Composition and methods for increasing insulin sensitivity
WO2007089318A2 (en) *	2005-11-23	2007-08-09	Orexigen Therapeutics, Inc.	Compositions and methods for reducing food cravings
US20110144145A1 (en)	2008-05-30	2011-06-16	Orexigen Therapeutics, Inc.	Methods for treating visceral fat conditions
CN102724878A (zh)	2010-01-11	2012-10-10	奥雷西根治疗公司	在重度抑郁症患者中提供体重减轻疗法的方法
PT2646031T (pt) *	2010-12-03	2017-05-25	Orexigen Therapeutics Inc	Aumento da biodisponibilidade farmacológica numa terapêutica com naltrexona
KR20220042241A (ko)	2012-06-06	2022-04-04	오렉시젠 세러퓨틱스 인크.	과체중 및 비만의 치료 방법
EP3253379A4 (en) *	2015-02-07	2018-10-10	Intas Pharmaceuticals Limited	Pharmaceutical composition for the treatment of obesity
ES2897790T3 (es) *	2017-03-28	2022-03-02	Ldn Pharma Ltd	Un agente que aumenta la expresión del agonista asociado a Bcl2 de la muerte celular para el tratamiento del cáncer
EP3482751A1 (en) *	2017-11-14	2019-05-15	LDN Pharma Limited	Cancer treatment
US12303604B1 (en)	2024-10-16	2025-05-20	Currax Pharmaceuticals Llc	Pharmaceutical formulations comprising naltrexone and/or bupropion

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE10129265A1 (de) *	2001-06-18	2003-01-02	Hf Arzneimittelforsch Gmbh	Wirkstoff-Kombination zur medikamentösen Sucht- oder Rauschmitteltherapie
US6972291B2 (en) *	2002-07-02	2005-12-06	Bernstein Richard K	Method for reducing food intake
EP1772147A2 (en) *	2003-03-17	2007-04-11	Japan Tobacco, Inc.	Method for increasing the oral bioavailability of S-[2-([[1-(2-ethylbutyl)cyclohexyl]carbonyl]amino)phenyl]-2-methylpropanethioate
MXPA05011557A (es) *	2003-04-29	2006-03-09	Orexigen Therapeutics Inc	Composiciones para afectar perdida de peso.
JP2009502931A (ja)	2005-07-27	2009-01-29	オレキシジェン・セラピューティクス・インコーポレーテッド	体重減少を促すための組成物
US8921344B2 (en) *	2006-11-03	2014-12-30	Salix Pharmaceuticals, Inc.	Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
EP2292220A3 (en)	2005-11-22	2012-01-04	Orexigen Therapeutics, Inc.	Composition and methods for increasing insulin sensitivity
WO2007089318A2 (en) *	2005-11-23	2007-08-09	Orexigen Therapeutics, Inc.	Compositions and methods for reducing food cravings
WO2007064586A1 (en)	2005-11-28	2007-06-07	Orexigen Therapeutics, Inc.	Methods of treating anxiety disorders
US8916195B2 (en)	2006-06-05	2014-12-23	Orexigen Therapeutics, Inc.	Sustained release formulation of naltrexone
DK2526932T3 (en)	2006-06-19	2017-07-17	Alpharma Pharmaceuticals Llc	Pharmaceutical composition
KR101264789B1 (ko)	2006-06-30	2013-05-15	엘지디스플레이 주식회사	횡전계 방식 액정표시장치용 어레이 기판과 그 제조방법
US7915307B2 (en) *	2006-07-20	2011-03-29	Somaxon Pharmaceuticals, Inc.	Methods of improving the pharmacokinetics of doxepin
CN101588795A (zh) *	2006-11-09	2009-11-25	奥雷西根治疗公司	包含中间快速溶解层的分层药物制剂
AU2007319472B2 (en)	2006-11-09	2013-01-17	Nalpropion Pharmaceuticals Llc	Methods Of Administering Weight Loss Medications
LT2545939T (lt) *	2007-04-11	2021-03-10	Biomarin Pharmaceutical Inc.	Tetrahidrobiopterinas, skirtas gydyti ligas, susijusias supadidėjusiu fenilalanino kiekiu
DE102007036076A1 (de)	2007-08-01	2009-02-05	Bayer Healthcare Aktiengesellschaft	Dipeptoid-Produgs und ihre Verwendung
US8318813B2 (en) *	2007-09-13	2012-11-27	Lcs Group, Llc	Method of treating binge eating disorder
US20110144145A1 (en)	2008-05-30	2011-06-16	Orexigen Therapeutics, Inc.	Methods for treating visceral fat conditions
PT2646031T (pt) *	2010-12-03	2017-05-25	Orexigen Therapeutics Inc	Aumento da biodisponibilidade farmacológica numa terapêutica com naltrexona

2011
- 2011-12-02 PT PT118451863T patent/PT2646031T/pt unknown
- 2011-12-02 LT LTEP21152314.7T patent/LT3884947T/lt unknown
- 2011-12-02 TW TW100144442A patent/TWI618536B/zh active
- 2011-12-02 EP EP23209711.3A patent/EP4349369B1/en active Active
- 2011-12-02 KR KR1020207011510A patent/KR102258043B1/ko active Active
- 2011-12-02 HU HUE17156985A patent/HUE053831T2/hu unknown
- 2011-12-02 DK DK17156985.8T patent/DK3222280T3/da active
- 2011-12-02 PT PT171569858T patent/PT3222280T/pt unknown
- 2011-12-02 MX MX2017013169A patent/MX384662B/es unknown
- 2011-12-02 FI FIEP21152314.7T patent/FI3884947T3/fi active
- 2011-12-02 LT LTEP17156985.8T patent/LT3222280T/lt unknown
- 2011-12-02 PL PL17156985T patent/PL3222280T3/pl unknown
- 2011-12-02 WO PCT/US2011/063177 patent/WO2012075459A1/en not_active Ceased
- 2011-12-02 ES ES17156985T patent/ES2866879T3/es active Active
- 2011-12-02 HR HRP20170734TT patent/HRP20170734T1/hr unknown
- 2011-12-02 LT LTEP11845186.3T patent/LT2646031T/lt unknown
- 2011-12-02 CA CA3239386A patent/CA3239386A1/en active Pending
- 2011-12-02 EP EP21152314.7A patent/EP3884947B1/en active Active
- 2011-12-02 BR BR112013013390A patent/BR112013013390A2/pt not_active Application Discontinuation
- 2011-12-02 PL PL21152314.7T patent/PL3884947T3/pl unknown
- 2011-12-02 PL PL11845186T patent/PL2646031T3/pl unknown
- 2011-12-02 SI SI201132102T patent/SI3884947T1/sl unknown
- 2011-12-02 SI SI201131967T patent/SI3222280T1/sl unknown
- 2011-12-02 HR HRP20240115TT patent/HRP20240115T1/hr unknown
- 2011-12-02 RS RS20210469A patent/RS62149B1/sr unknown
- 2011-12-02 HU HUE11845186A patent/HUE034393T2/en unknown
- 2011-12-02 SI SI201131199A patent/SI2646031T1/sl unknown
- 2011-12-02 RS RS20240196A patent/RS65198B1/sr unknown
- 2011-12-02 SM SM20170232T patent/SMT201700232T1/it unknown
- 2011-12-02 AU AU2011336304A patent/AU2011336304B2/en active Active
- 2011-12-02 FI FIEP23209711.3T patent/FI4349369T3/fi active
- 2011-12-02 ES ES11845186.3T patent/ES2625527T3/es active Active
- 2011-12-02 KR KR1020187016354A patent/KR101984500B1/ko active Active
- 2011-12-02 AR ARP110104512A patent/AR093182A1/es not_active Application Discontinuation
- 2011-12-02 CA CA2819262A patent/CA2819262C/en active Active
- 2011-12-02 JP JP2013542229A patent/JP6008866B2/ja active Active
- 2011-12-02 EP EP11845186.3A patent/EP2646031B9/en active Active
- 2011-12-02 PT PT211523147T patent/PT3884947T/pt unknown
- 2011-12-02 CN CN2011800638854A patent/CN103313711A/zh active Pending
- 2011-12-02 KR KR1020137017317A patent/KR20140035320A/ko not_active Ceased
- 2011-12-02 DK DK11845186.3T patent/DK2646031T3/en active
- 2011-12-02 SM SM20240038T patent/SMT202400038T1/it unknown
- 2011-12-02 RS RS20170491A patent/RS56014B1/sr unknown
- 2011-12-02 MX MX2013006071A patent/MX356801B/es active IP Right Grant
- 2011-12-02 US US13/991,137 patent/US20130245056A1/en not_active Abandoned
- 2011-12-02 KR KR1020217015625A patent/KR102391511B1/ko active Active
- 2011-12-02 SM SM20210227T patent/SMT202100227T1/it unknown
- 2011-12-02 RU RU2013127423A patent/RU2640561C2/ru active
- 2011-12-02 HU HUE21152314A patent/HUE065852T2/hu unknown
- 2011-12-02 KR KR1020197014576A patent/KR102105857B1/ko active Active
- 2011-12-02 EP EP17156985.8A patent/EP3222280B1/en active Active
- 2011-12-02 DK DK21152314.7T patent/DK3884947T3/da active
2013
- 2013-05-23 IL IL226504A patent/IL226504B/en active IP Right Grant
- 2013-05-31 CL CL2013001564A patent/CL2013001564A1/es unknown
2016
- 2016-09-12 JP JP2016177391A patent/JP6456890B2/ja active Active
2017
- 2017-05-18 CY CY20171100524T patent/CY1118968T1/el unknown
- 2017-06-26 AU AU2017204309A patent/AU2017204309A1/en not_active Abandoned
2018
- 2018-12-19 JP JP2018237245A patent/JP7025319B2/ja active Active
2019
- 2019-11-21 IL IL270841A patent/IL270841A/en unknown
2020
- 2020-12-21 IL IL279626A patent/IL279626A/en unknown
2021
- 2021-04-19 HR HRP20210618TT patent/HRP20210618T1/hr unknown
- 2021-04-19 CY CY20211100340T patent/CY1124331T1/el unknown
- 2021-12-23 AR ARP210103655A patent/AR124500A2/es unknown
2022
- 2022-02-10 JP JP2022019546A patent/JP2022060331A/ja active Pending
2024
- 2024-03-27 JP JP2024051334A patent/JP2024071605A/ja active Pending

Also Published As

Publication number	Publication date
RU2017144631A (ru)	2019-02-18
PL2646031T3 (pl)	2017-08-31
RS56014B1 (sr)	2017-09-29
EP2646031A1 (en)	2013-10-09
HRP20240115T1 (hr)	2024-06-07
BR112013013390A2 (pt)	2016-09-06
CA2819262A1 (en)	2012-06-07
SI2646031T1 (sl)	2017-07-31
WO2012075459A1 (en)	2012-06-07
PT3884947T (pt)	2024-02-16
RU2013127423A (ru)	2015-01-10
PL3884947T3 (pl)	2024-05-06
JP2022060331A (ja)	2022-04-14
AR093182A1 (es)	2015-05-27
CA3239386A1 (en)	2012-06-07
FI4349369T3 (fi)	2025-12-17
LT2646031T (lt)	2017-06-26
JP7025319B2 (ja)	2022-02-24
DK2646031T3 (en)	2017-05-22
CN103313711A (zh)	2013-09-18
DK3884947T3 (da)	2024-01-22
EP2646031B1 (en)	2017-02-22
EP3222280B1 (en)	2021-01-20
MX2013006071A (es)	2013-10-01
EP3884947B1 (en)	2023-11-15
RU2640561C2 (ru)	2018-01-09
SI3884947T1 (sl)	2024-06-28
KR20200044158A (ko)	2020-04-28
SMT202100227T1 (it)	2021-07-12
HUE065852T2 (hu)	2024-06-28
CA2819262C (en)	2024-05-28
IL226504B (en)	2021-01-31
IL279626A (en)	2021-03-01
RS62149B1 (sr)	2021-08-31
FI3884947T3 (fi)	2024-01-30
MX356801B (es)	2018-06-13
SI3222280T1 (sl)	2021-11-30
TWI618536B (zh)	2018-03-21
HUE053831T2 (hu)	2021-07-28
ES2625527T3 (es)	2017-07-19
MX384662B (es)	2025-03-14
KR20210063473A (ko)	2021-06-01
CY1118968T1 (el)	2018-01-10
JP2016210809A (ja)	2016-12-15
EP3222280A1 (en)	2017-09-27
SMT202400038T1 (it)	2024-03-13
DK3222280T3 (da)	2021-04-19
TW201304780A (zh)	2013-02-01
EP3884947A1 (en)	2021-09-29
HRP20170734T1 (hr)	2017-08-11
KR102105857B1 (ko)	2020-05-04
HRP20210618T1 (hr)	2021-09-17
KR20140035320A (ko)	2014-03-21
JP6008866B2 (ja)	2016-10-19
HUE034393T2 (en)	2018-02-28
ES2866879T3 (es)	2021-10-20
JP2013544290A (ja)	2013-12-12
EP2646031A4 (en)	2014-04-23
PT2646031T (pt)	2017-05-25
KR101984500B1 (ko)	2019-05-31
EP4349369A2 (en)	2024-04-10
KR20190058702A (ko)	2019-05-29
RS65198B1 (sr)	2024-03-29
JP6456890B2 (ja)	2019-01-23
JP2019056004A (ja)	2019-04-11
AU2011336304A1 (en)	2013-07-11
ES2625527T9 (es)	2018-09-25
AR124500A2 (es)	2023-04-05
EP2646031B9 (en)	2018-01-10
PL3222280T3 (pl)	2021-11-29
AU2011336304B2 (en)	2017-03-30
EP4349369A3 (en)	2024-05-15
IL270841A (en)	2020-01-30
RU2017144631A3 (pt)	2021-04-13
US20130245056A1 (en)	2013-09-19
LT3884947T (lt)	2024-03-12
JP2024071605A (ja)	2024-05-24
CY1124331T1 (el)	2022-07-22
EP4349369B1 (en)	2025-09-17
CL2013001564A1 (es)	2014-05-02
LT3222280T (lt)	2021-05-10
KR102258043B1 (ko)	2021-05-28
KR102391511B1 (ko)	2022-04-26
KR20180069089A (ko)	2018-06-22
SMT201700232T1 (it)	2017-07-18
AU2017204309A1 (en)	2017-07-13

Publication	Publication Date	Title
IL279626A (en)	2021-03-01	Increasing the bioavailability of a drug in treatment with naltrexone
GB2479953B (en)	2015-04-29	Drug delivery device
IL226245A0 (en)	2013-07-31	History
IL221007A (en)	2016-06-30	Pharmaceutical combinations for antiviral therapy
ZA201209197B (en)	2016-08-31	Drug delivery device
SG10202001055YA (en)	2020-04-29	Drug delivery device
PL2560624T3 (pl)	2019-01-31	Formulacja terapeutyczna do zmniejszania skutków ubocznych leku
GB201010193D0 (en)	2010-07-21	Medicinal use
EP2643000A4 (en)	2014-05-21	THERAPEUTIC PIPERAZINES
EP2575887A4 (en)	2015-01-14	CONJUGATES OF OPTIMIZED MEDICINES
GB201017597D0 (en)	2010-12-01	Drug detection
ZA201208185B (en)	2014-03-26	Intravaginall drug delivery device
HRP20141173T1 (hr)	2015-01-30	Medikament koji sadrži miramistin
GB201016864D0 (en)	2010-11-17	Therapeutic methods
EP2626055A4 (en)	2014-04-16	ACTIVE RELEASE DEVICE
GB201019527D0 (en)	2010-12-29	Redox drug derivatives
GB201006112D0 (en)	2010-05-26	Redox drug derivatives
PL390434A1 (pl)	2011-08-16	Preparat leczniczy
PL390620A1 (pl)	2011-09-12	Preparat farmaceutyczny
GB201003514D0 (en)	2010-04-21	Improvements in antibacterial drugs